To explore the efficacy and safety of "Manpixiao" in the treatment of Chronic Atrophic Gastritis.

Inclusion Criteria:

• The age is 18-75 years old, regardless of gender;
• Before treatment, the patients were diagnosed as chronic atrophic gastritis (with intestinal metaplasia and dysplasia) by gastroscopy and pathological examination, which met the criteria of the Chinese consensus on chronic gastritis (2017, Shanghai);
• Sign the informed consent form.

Exclusion Criteria:

• Patients with autoimmune gastritis (chronic atrophic gastritis type A), peptic ulcer (a1-h2), reflux esophagitis, gastric polyps, hypertrophic gastritis and other diseases;
• Patients with high-grade intraepithelial neoplasia of gastric mucosa, suspected malignant change of gastrointestinal mucosal lesions, and gastrointestinal tumors;
• Patients with malignant tumors who have undergone surgery, radiotherapy and chemotherapy in recent 5 years;
• Patients with primary diseases such as heart, brain, lung, hematopoietic system and malignant tumors, and subjects with severe diabetes;
• Patients with chronic liver and kidney dysfunction before treatment, including ALT > 1.5 times the upper limit of normal value, blood creatinine (CR) > 1.5 times the upper limit of normal value, and platelets lower than 1.5 times the lower limit of normal value;
• Disabled subjects specified by law (blind, deaf, dumb, intellectual, mental, physical disabilities);
• The description of self symptoms is unclear or the investigation is not the author;
• Have a history of alcohol abuse;
• Allergic constitution or a history of allergy to multiple drugs (more than two or known ingredients in the drug);
• Pregnant or lactating women;
• According to the judgment of the researcher, other reasons should not be selected.

Obtained by asking the first or correspondent author if necessary

One year after the completion of the study

Obtained by asking the first or correspondent author if necessary